The development of the dual inhibitor XL765 (Voxtalisib) targeting both PI3K and mTOR pathways to block the compensatory response has shown a potent reduction of tumor growth in a patient‐derived GBM xenograft model [83]. This evidence concerns the gene PIK3CA and neoplasm.